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The approval of medicinal products is a hi-
ghly regulated field. The birth of the unified 
European legislation of medicines took place 
in 1965 with the adoption of Directive 65/65/
CEE [1]. The sponsor of any new medici-
nal product should demonstrate the quality, 
the safety and the efficacy of a drug prior to 
being granted the permission by the relevant 
health authorities to put the product on the 
market at the disposal of patients. The Euro-
pean Medicines Agency (EMA), the scienti-
fic body responsible for performing the eva-
luation, provides a scientific opinion to the 
European Commission (EC), which will then 
serve as the basis for the marketing authori-
zation, which will have automatic validity in 
all European Union (EU) member states.
HTA is taking more and more relevance every 
day, for authorities, for payers and for indu-
stry. Proven quality, safety and efficacy, the 
three basic guarantees are no longer enough 
to allow patients access to a new medicine. 
Now, a medicinal product also has to demon-
strate its relative cost-effectiveness, when 
compared to other available treatments, the 
so-called fourth guarantee in order to receive 
IntroductIon
Health authorities assess the quality, safety 
and efficacy of a medicinal product1 based on 
its own merits whereas Health Technology 
Assessment (HTA) bodies evaluate the safety 
and efficacy of a drug comparatively to other 
available treatments on the market, as well 
as its cost-effectiveness. As a consequence, 
industry faces the challenge that the data set 
required to undertake the two evaluations 
could not be necessarily the same. In such a 
context, it is of extreme importance to design 
correctly from the start the expensive clinical 
programs with the aim of fulfilling the obli-
gations for the two areas of assessment effi-
ciently and in parallel.
European health authorities, including regu-
latory and HTA bodies, recognizing all these 
challenges and the existing room for har-
monization have initiated the path towards 
knowledge sharing and collaboration in order 
to reach and establish common approaches.
1 The terms medicinal product, medicine and drug are used 
as synonyms.
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AbstrAct
In order to reach the European market, a new drug needs to receive a positive evaluation regarding its quality, safety 
and efficacy by regulatory health authorities and also obtain a positive HTA appraisal regarding its cost-effectiveness by 
HTA bodies. Regulators and HTA bodies are collaborating in several projects at European level in order to harmonize the 
scientific requirements of both evaluations to the maximum extent possible. The comparison of the regulatory evaluation 
performed by EMA for Kalydeco and the HTA appraisals issued by several EU bodies exemplifies the dilemma between 
scientific evidence and local economic considerations and the difficulties in the achievement of harmonization and there-
fore equity in the access to drugs. 
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a positive appraisal by HTA bodies and suc-
cessful reimbursement negotiations.
An important milestone has been reached in 
Europe in this context with the establishment 
of the European Union Network of HTA (EU-
netHTA) [2]. In 2004, the EC and the Council 
of the EU recognized the Health Technology 
Assessment as a high priority and urged for 
establishing a sustainable European network 
on HTA. In 2005, a group of 35 organizations 
throughout Europe began the activities of the 
EUnetHTA Project. One of the most impor-
tant milestones achieved by EUnetHTA is 
the creation of a Core harmonized Model for 
HTA appraisals, where the key elements to be 
evaluated by HTA bodies are represented [3].
As a response to the recommendations from 
the Pharmaceutical Forum in 2008, the 
EMA and EUnetHTA initiated a collabora-
tion to improve the contribution that Euro-
pean Public Assessment Reports (EPARs) 
prepared by EMA could make to the asses-
sment of relative effectiveness of medicinal 
products [4].
The EU Directive 2011/24/EU [5] on the ap-
plication of patients’ rights in cross-border 
healthcare set a milestone in the recognition 
of equity in rights across European Union 
Members States and also introduced impor-
tant provisions for the EU collaboration in 
the area of rare diseases and HTA.
Kalydeco (ivacaftor), is recognized as being 
the first in a new class of medicines: Cystic 
Fibrosis Transmembrane Conductance Regu-
lator (CFTR) potentiators. It targets the cystic 
fibrosis CFTR and so treats the underlying 
cause of the disease. It increases the time that 
activated CFTR channels remain open at the 
cell surface. Kalydeco is one the drugs that 
has received orphan designation for cystic fi-
brosis [6] and one of the seven drugs [7] for 
which the European Medicines Agency has 
adopted a positive opinion for cystic fibrosis. 
Kalydeco is at the moment one of the most 
expensive drugs in Europe. The annual price 
of the drug per patient makes it difficult to for 
some national budgets to absorb the cost [8].
The objective of this study was on the one 
hand to identify the elements that regula-
tors and HTA bodies took into account when 
performing their respective evaluations of 
Kalydeco. And, on the other hand, to ascer-
tain the origin of the divergent opinions iden-
tified among HTA bodies when confronted 
with the same clinical evidence.
Methodology
The EPAR for Kalydeco issued by the EMA 
in 2012 was taken as the reference document 
for the regulators evaluation [9].
The publicly available HTA appraisals in En-
glish, Spanish and German from European 
HTA bodies were taken as reference for this 
analysis. The selected reports correspond to 
the following HTA bodies2:
 - Scottish Medicines Consortium (SMC) – 
UK Scotland [10];
 - NHS England statement (NHS) – UK En-
gland [11];
 - Therapeutic Positioning Report for Spa-
nish Government (IPT) – Spain [12];
 - Institut für Qualität und Wirtschaftli-
chkeit im Gesundheitswesen (IQWIG) – 
Germany [13];
 - National Center for Pharmacoeconomics 
(NCPE) – Ireland [14];
 - Haute Autorité de Santé (HAS) – France 
[15].
A comparative analysis of the information 
contained in the EPAR and the HTA reports 
was undertaken following the 3 steps scheme 
described below:
1. Analysis following the HTA Core Model 
developed by EUnetHTA to determine the 
domains common to the regulatory and 
HTA fields;
2. Analysis of the study design elements 
which are frequently source of discrepan-
cies between regulators and HTA bodies 
(i.e. comparators, study population and 
endpoints);
3. Analysis of the clinical evidence ele-
ments available pre-approval. The items 
considered were the benefit/risk balance, 
post-approval studies, degree of uncer-
tainty and clinical added value. Study 
of the similarities and differences in the 
opinions among HTA bodies in view of 
the same clinical evidence which is taken 
from the EPAR published by the EMA3.
results
Each table contains a summary of the in-
formation present in the EPAR and HTA 
reports studied. The EUnetHTA Core Mo-
del (Table I) defines the domains that HTA 
bodies should study for their appraisals. Not 
all these domains are relevant for the regu-
latory assessment. In addition, the analysis 
showed that not all HTA reports considered 
all domains and also the depth and detail in 
which the same domains were addressed was 
different too.
2 All these HTA bodies have an advisory role but are not the 
ultimate decision maker in their respective countries.
3 The clinical studies considered as sources of information 
were the same both in the EPAR and in the HTA reports (i.e. 
STRIVE, ENVISION and PERSIST). HTA bodies had more 
data (i.e. longer periods) from PERSIST study available at 
the time of appraisal than EMA.
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The analyses showed that the clinical study 
design was considered appropriate in all HTA 
reports (Table II). No divergent opinions in 
this area were pointed out between regulators 
and HTA bodies. The elements analysed un-
der this area showed differences in opinions 
among HTA bodies, indicating variations in 
the acceptance of the degree of uncertainty 
regarding the long-term safety and effica-
cy. From the six HTA reports studied, four 
countries acknowledged the uncertainty pre-
sent but accepted it. Two bodies, the NCPE 
of Ireland and the SMC of Scotland did not.
The appraisal of the clinical added value 
(i.e. relative cost effectiveness) also varies 
among HTA bodies (Table III). No discus-
sion at all is present in the French and Spa-
nish reports. In the German report only glo-
bal budget considerations are present. The 
English, Scottish and Irish reports address 
the pharmacoeconomic studies provided 
by the Sponsor together with Incremental 
Cost Effectiveness Ratio (ICER) and Qua-
lity Adjusted Life Year (QALY) threshold 
elements in addition to global budget con-
siderations.
Elements
EPar information:
What is sought to grant a 
Marketing Authorization?
HTa reports information:
What is sought for pricing and reimbursement?
Health problem 
and current use
D. Main elements of the disease 
described.
nHs: D. Estimation of number of patients eligible provided (≈270).
sMC: D. Estimation of number of patients eligible provided (≈70).
iPT: D. Estimation of number of patients eligible provided (≈16).
nCPE: D. Estimation of number of patients eligible provided (≈120).
Has: D. Estimation of number of patients eligible provided (≈74).
iQWig: D. Estimation of number of patients eligible provided (≈180).
Description 
and technical 
characteristics
D. Main elements:
Marketing authorization (MA) date
Indication
Posology
nHs: D
sMC: D
iPT: D
nCPE: D
Has: D
iQWig: D
safety D. The most frequent adverse 
reactions were not severe and well 
tolerated.
nHs: ND
sMC: D. Based on EPAR.
iPT: D. Based on EPAR. The two post-authorisation measures 
imposed on the MA mentioned as source of further information.
nCPE: ND
Has: D. Based on EPAR.
iQWig: ND.
Clinical 
effectiveness
D. Observational studies imposed 
as a condition on the marketing 
authorization.
Details discussed in Tables II and III.
nHs: D. Details discussed in Tables II and III.
sMC: D. Details discussed in Tables II and III.
iPT: D. Details discussed in Tables II and III.
nCPE: D. Details discussed in Tables II and III.
Has: D. Details discussed in Tables II and III.
iQWig: ND.
Costs and 
economic 
evaluation
NA. nHs: D. Details discussed in Tables II and III.
sMC: D. Details discussed in Tables II and III.
iPT: ND.
nCPE: D. Details discussed in Tables II and III.
Has: ND.
iQWig: D. Details discussed in Tables II and III.
Ethical analysis NA. nHs: D. First drug in class. Severity of the disease. Improvement of 
health, reduction of hospitalizations. Indicated for children when the 
damage in tissues could be still slowed down. Mention to the fact that 
similar ultra-orphan drugs previously financed with similar ICER ranges.
sMC: D. First drug in class. Incurable disease.
iPT: D. First drug in class.
nCPE: D. First drug in class.
Has: D. First drug in class.
iQWig: ND.
Organizational 
aspects
D. The medicine was authorized 
subject to restricted medical 
prescription (i.e. by specialists) and 
subject to genetic diagnosis of the 
mutation.
Monitoring system by registries.
nHs: D. Genetic diagnosis required and sweat chloride levels 
controls. Prescribed by specialists. Health outcomes to be monitored 
by cystic fibrosis registries.
sMC: D. Based on EPAR indication.
iPT: D. Based on EPAR indication.
nCPE: ND.
Has: D. Based on EPAR indication.
Hospital use.
iQWig: ND.
continue >
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social aspects NA. nHs: ND.
sMC: ND.
iPT: ND.
nCPE: ND.
Has: ND.
iQWig: ND.
legal aspects NA. nHs: ND.
sMC: ND.
iPT: ND.
nCPE: ND.
Has: ND.
iQWig: ND.
Table i. EUnetHTA Core Model
D = element discussed in the report (i.e EPAR/HTA; HAS = Haute Autorité de Santé; IPT = Therapeutic Positioning Report for Spanish Government; 
IQWIG = Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen; NA = not applicable to the evaluation; ND = element not discussed in the report 
(i.e. EPAR/HTA); NCPE= National Center for Pharmacoeconomics; NHS = NHS England statement; SMC = Scottish Medicines Consortium
Elements
EPar information:
What is sought to grant a Marketing 
Authorization?
HTa reports information:
What is sought for pricing and reimbursement?
Comparators
Placebo vs. Active
D. Kalydeco was compared to placebo in two 
Phase III pivotal trials (double-blind, randomized, 
multicentre):
STRIVE on adults (VX08-770-102) and ENVISION 
on children
(VX08-770-103)
The Standard of Care (SOC) (i.e. pre-study 
medication) was continued in the patients with 
the exception of the inhaled hypertonic saline, 
which was not allowed.
nHs: D. Statement that 2 well conducted research 
studies (one in adults/one in children) placebo-
controlled trials were undertaken. Only palliative 
treatments are currently available.
sMC: D. Superiority over placebo showed. There 
are no comparators for the disease.
iPT: D. Currently only symptomatic treatments are 
available.
nCPE: ND.
Has: D. Currently only symptomatic treatments are 
available.
iQWig: ND.
study population
Homogeneous vs. 
Heterogeneous
D. Two main studies involving 219 patients with 
cystic fibrosis who had the G551D mutation in 
at least one allele of the CFTR gene: one of the 
studies was in patients >12 years old (n.=167) 
(STRIVE), the other study involved patients 
between 6 and 12 years (n.=52) (ENVISION). In 
addition, patients included had a FEV1 ≥ 40% 
and a minimum body weight of 15 kg1.
nHs: ND.
sMC: D. The small size is acknowledged as 
appropriate considering the low number of patients 
affected by the mutation.
iPT: D. The small size is acknowledged as 
appropriate considering the low number of patients 
affected by the mutation.
nCPE: ND.
Has: D. Based on EPAR.
iQWig: ND.
Endpoints (Patient 
Reported Outcomes – 
PROs, Quality of Life 
–QoL, Duration of Life, 
etc.).
D. The studies mentioned above had 48 weeks 
of duration.
The main measure of efficacy was the ability to 
improve the pulmonary function (measured as 
the absolute change from baseline in percent 
predicted FEV1 after 24 weeks of treatment). This 
variable was also measured at week 48.
Secondary variables: other beneficial aspects 
as decrease rate of pulmonary exacerbations, 
sweat chloride concentration and increase in 
body weight.
In addition, the change in respiratory symptoms 
at week 24 and 48 evaluated through the 
validated CFQ-R questionnaire2. 
PERSIST study (VX08-770-105) is an extension, 
non-controlled open-label study of studies VX08-
770-102 and 103, the two pivotal trials presented 
for the marketing authorization application. The 
open-label study is up to 96 weeks (i.e. 144 
weeks of treatment for those already on the drug 
and 96 for those initially allocated to placebo).
nHs: D. Improved lung function, weight gain 
and decrease in worsening of breathing requiring 
other treatments. Note is made to the absence of 
long-term efficacy data but it is recognized that 
the main indicator of cystic fibrosis, the amount of 
salt in sweat returns to normal values with ivacaftor 
treatment).
Indication of the extension, non-controlled open-
label study up to 96 weeks.
sMC: D. Acknowledgement of FEV1 as a surrogate 
which is the recommended primary clinical endpoint 
for efficacy studies. CFQ-R mentioned. PERSIST 
study (up to 96 weeks) also mentioned.
iPT: D. Based on EPAR. Indication of the extension, 
non-controlled open-label study up to 96 weeks 
(PERSIST).
nCPE: D. Brief reference to FEV1 as primary 
endpoint for Phase III clinical trials.
Has: D. Based on EPAR. Indication of the 
extension, non-controlled open-label study up to 96 
weeks (PERSIST).
iQWig: ND.
Table ii Clinical study Design
1 FVE1 is the maximum amount of air that a person can breathe out in one second
2 CFQ-R Questionnaire. In the CFQ-R, patients report respiratory symptoms. It is an indicator of the symptoms on the quality of life.
D = element discussed in the report (i.e EPAR/HTA; HAS = Haute Autorité de Santé; IPT = Therapeutic Positioning Report for Spanish Government; 
IQWIG = Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen; NA = not applicable to the evaluation; ND = element not discussed in the report 
(i.e. EPAR/HTA); NCPE= National Center for Pharmacoeconomics; NHS = NHS England statement; SMC = Scottish Medicines Consortium
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Elements
EPar information:
What is sought to grant a Marketing 
Authorization?
HTa reports information:
What is sought for pricing and reimbursement?
Positive benefit/risk balance
(Quality, Safety and Efficacy: 
The 3 basic guarantees)
D.
Quality: positive
Safety: positive. Minor side effects.
Efficacy: positive.
After 24 weeks of treatment, patients aged 
12 years and older who took Kalydeco had 
an average improvement in FEV1 of 10.4%, 
compared with a reduction of 0.2% in those 
who took placebo. Similar results were 
seen in patients aged between 6 and 11 
years, where Kalydeco treatment led to an 
improvement in FEV1 of 12.6% compared 
with an improvement of 0.1% with placebo.
These efficacy values were maintained at 
week 48.
nHs: D. Based on EPAR.
sMC: D. Based on EPAR.
iPT: D. Based on EPAR.
Efficacy explicitly acknowledged.
nCPE: ND.
Has: D. Based on EPAR.
iQWig: ND.
Post-approval studies
(Generation of additional 
evidence: PASS, PAES, 
Registries).
D. PASS and PAES imposed as a condition 
of the Marketing Authorisation. Real world 
data collection as part of these studies 
required.
nHs: D. Mention to PERSIST study. Mention that 
health outcomes in patients taking ivacaftor will 
be monitored using data from the cystic fibrosis 
registry.
sMC: D. Long-term studies are acknowledged.
iPT: D. The studies imposed on the MA are 
acknowledged and recognized as useful to clarify 
pending long-term safety and efficacy evidence 
generation.
nCPE: ND.
Has: Discussed. Based on EPAR.
iQWig: ND.
Degree of uncertainty 
accepted
D.
EPAR indicates limited data on longer-term 
effects.
Conditions were imposed on the MA to 
provide further data in this respect:
From an ongoing long-term study and to 
conduct a five-year observational study.
nHs: D. Good evidence that ivacaftor is 
clinically effective although long-term safety and 
effectiveness data beyond 96 weeks are lacking.
Monitoring of sweat chloride test required as 
indicators of treatment effectiveness and used 
as a stopping criteria for the treatment to be 
discontinued.
sMC: D. The PERSIST study is acknowledged.
But long-term efficacy and safety data are 
considered necessary for chronic conditions and 
data beyond 48 weeks are limited.
iPT: D. Absence of long-term efficacy data to 
prove maintenance of positive effects accepted. 
Monitor the efficacy in patients receiving 
treatment.
nCPE: D. Absence of long-term efficacy and 
safety data not accepted. 96 weeks in adults and 
72 in children considered limited.
Has: D. Absence of long-term efficacy data to 
prove maintenance of positive effects accepted.
iQWig: ND.
Clinical added value
(Relative Cost-Effectiveness: 
The 4th guarantee).
NA. nHs: D. ICER and QALY. No global budget 
discussion. Ivacaftor reduces need for other 
expensive treatments for progressive clinical 
deterioration and need of hospital care, including 
organ transplantation, which accounts for £100m 
annual expenditure (excluding transplantation).
sMC: D. ICER, QALY and global budget figures 
provided.
iPT: ND.
nCPE: D. ICER, QALY and general budget 
considerations. Out of the accepted 45000 Euro/ 
QALY threshold.
Has: ND.
iQWig: Global budget discussion.
Table iii. Clinical evidence pre-approval
D = element discussed in the report (i.e EPAR/HTA; HAS = Haute Autorité de Santé; IPT = Therapeutic Positioning Report for Spanish Government; 
IQWIG = Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen; NA = not applicable to the evaluation; ND = element not discussed in the report 
(i.e. EPAR/HTA); NCPE= National Center for Pharmacoeconomics; NHS = NHS England statement; PAES: Post-Authorisation Efficacy Study; PASS: Post-
Authorisation Safety Study; SMC = Scottish Medicines Consortium
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of this expensive treatment in their public he-
alth systems.
Nevertheless, despite the negative recom-
mendations issued by the Scottish Medicines 
Consortium and the National Center for Phar-
macoeconomics of Ireland, the governments 
of these two countries finally decided to 
make the drug available, being the decision 
ultimately raised to the political level.
It is also to be mentioned that outside the 
EU, similar conclusions were reached. The 
Canadian Drug Expert Committee (CDEC) 
recommended in March 2013 ivacaftor un-
der the condition of a substantial reduction 
in price to meet cost-effectiveness criteria 
[16]. The Pharmaceutical Benefits Advisory 
Committee (PBAC) in Australia reflected in 
March 2014 that without a substantial price 
reduction or a pay for performance arrange-
ment, ivacaftor would not be considered cost-
effective [17].
conclusIon
The case of Kalydeco exemplifies the dilem-
ma between the scientific clinical evidence 
and the national budget considerations that 
HTA bodies face. Kalydeco was undoubtedly 
and unanimously recognized at EU level by 
regulators on the three first basic guarantees. 
However, the granting of an EU marketing 
authorization is not to be taken for granted 
as synonym of equal access to European pa-
tients. Some national HTA bodies can con-
clude that financing and reimbursement re-
quirements are not met and therefore block 
entrance into their respective markets.
In such a situation, will the disharmony 
among European countries be solved if a 
common core HTA method and efficient sha-
ring of data were established among HTA 
bodies? The example of Kalydeco evidences 
that the solution might not be so simple, as it 
is clear that the clinical evidence can be over-
ruled by price and budget considerations.
In the last two decades, regulatory agencies 
have enormously increased the level of har-
monization, communication and transpa-
dIscussIon
From the point of view of the scientific evi-
dence, all the HTA reports analysed obtained 
the main clinical elements regarding safety 
and efficacy from the published EPAR (Table 
IV). None of the HTA reports challenged the 
design of the studies or the clinical evidence 
generated.
However, there was a clear difference in the 
way the existing degree of uncertainty was 
evaluated, being this aspect the key point in 
the justification of the negative opinions rea-
ched by the Irish and Scottish HTA bodies.
All HTA reports alluded to the presence of 
uncertainty regarding long term effects. In 
fact, this aspect is well reflected in the EPAR. 
The EMA opinion noted the limited data on 
longer-term effects and as a result imposed 
conditions on the marketing authorization in 
this respect (provision of on-going long-term 
study and the conduct of a five-year observa-
tional study).
However, while for NHS England, Spain, 
France and Germany this degree of uncer-
tainty was considered acceptable and did not 
preclude a positive financing decision, for the 
Scottish and Irish HTA bodies this represen-
ted the scientific clinical evidence factor hi-
ghlighted and emphasized in order to support 
the negative opinion. 
From a cost-effectiveness point of view, the 
Irish and Scottish HTA bodies were clear re-
garding that Kalydeco is not cost-effective. 
NHS England and Germany highlighted the 
high cost of the drug but still considered it 
financeable due to the characteristics of the 
drug and the illness. The Spanish and French 
HTA reports provided estimations to the 
number of patients eligible for the treatment 
in their respective countries but do not repor-
ted further on cost-effectiveness elements.
The HTA reports of NHS England, SCM and 
Ireland indicated the fact that the public ad-
ministration engaged in price negotiations 
with the holder Vertex Pharmaceuticals or 
would be willing to do it in order to agree 
discounts that would facilitate the financing 
Country safety & Efficacy
Uncertainty 
accepted
Price and budget 
considerations
recommendation
Final government 
decision
Spain + Yes No Positive Positive
France + Yes No Positive Positive
Germany + Yes Yes Positive Positive
England + Yes Yes Positive Positive
Scotland + No Yes Negative Positive
Ireland + No Yes Negative Positive
Table iV. Summary of key decision elements
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ensure predictability and facilitate as much as 
possible patient’s early access to new medi-
cines. A disharmony in this area would also 
raise controversy across patient’ organiza-
tions as it will become difficult to justify that 
in the framework of the European Union not 
all patients enjoy the same degree of health 
protection. However, in this subject of access 
and equity, not only regulators should be seen 
as the only responsible party. Industry also 
has a responsible role to play. Regulators and 
HTA bodies are taking important steps and 
efforts to harmonize criteria and are willing 
to embark in a transparent dialogue with in-
dustry to facilitate the development of new 
drugs. But at the same time, sponsors of the 
new medicines also need to be aware of the 
European governments’ obligation to assure 
the long term sustainability of their health 
systems.
rency in relation to their assessment proces-
ses. HTA bodies in Europe are now working 
to achieve the same degree of harmonization 
and collaboration for HTA process and find 
a common path where both evaluation meet 
and align. However, the local focus that the 
financing perspective has cannot be obviated 
and as a result, different national conclusions 
can arise from the same clinical evidence. 
Some of them could be due to the selection 
of different factors for the analysis or the out-
come of the importance and interpretation gi-
ven based on local specificities and values or 
on national cost-effectiveness thresholds and 
budget’s restrictions.
Regulators and HTA bodies are aware of the 
need to provide industry with clear guideli-
nes for the development of new medicines 
and are willing to engage in a transparent and 
productive dialogue with industry in order to 
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